Supplementary Information accompanies the paper on the Leukemia website (http://www.nature.com/leu) High risks of familial chronic lymphatic leukemia for specific relatives: signposts for genetic discovery? Chronic lymphatic leukemia (CLL) presents a very high familial aggregation, 1,2 with a relative risk for first-degree relatives of CLL patients close to 8. In order to help understand the possible genetic mechanism for CLL inheritance, we conducted an in-depth investigation of the concordance in adult family members for CLL, focusing on the type of familial relationship and sex. Taking advantage of a large population-based database linked to information on family relationships, we examined how the type of kinship and sex affect the familial risk of adult CLL. We identified CLL cases diagnosed in Sweden over a period of almost 50 years, and compared the risk of CLL in their first-degree relatives to the risk in the first-degree relatives of matched individuals (controls) who were free of cancer.
The 'Multi-Generation Register' maintained by Statistics Sweden 3 records the identities of the biological parents of all children born in Sweden since 1932 (and alive in 1960). We obtained a copy of this database containing a total of 11 million individuals. Using the unique national registration number, these individuals were linked to the Swedish Cancer Register to identify all first primary malignancies diagnosed between 1958 (the startup date of the register) and 2007. CLL was identified using the International Classification of Diseases, Seventh Revision (ICD7 code 204.1).
Cases were defined as Swedish-born individuals more than 15 years old who had a first primary diagnosis of CLL in the study period (1 January 1958 to 31 December 2007) and for whom at least one first-degree relative could be identified through the Multi-Generation register. For each case, we randomly sampled from our database up to five controls born in Sweden who were cancer-free at the time of diagnosis of the case and for whom at least one first-degree relative was found. Controls were matched to the case for gender, year of birth and country of residence at the previous census year closest to the diagnosis. This last matching was to account for regional variability in diagnosing and reporting of malignancies. We will refer to the cases and controls as 'probands'. For each proband, we identified all first-degree relatives (parents, siblings and offspring) and followed these from age 15 years for a diagnosis of CLL. Record linkages with the nationwide Cause of Death and Total Population registers allowed complete follow-up with regard to vital status and date of death, as well as dates of emigration and immigration. All data preparation and analysis was performed using SAS 9.2. The study was approved by the Stockholm regional ethics committee.
From the linked database, we identified 14 112 cases born in Sweden who were more than 15 years old when they had a first primary diagnosis of CLL. For 9335 of these, we could identify at least one relative with follow-up after the age of 15. We excluded 192 cases owing to missing country of residence (n ¼ 54) or lack of matched controls with any registered relative with follow-up after the age of 15 (n ¼ 138). Among the remaining 9143 cases of CLL, there were more males (5801, 63.4%) than females (3342, 36.6%), consistent with a recent review. 4 The median age at diagnosis was 69 (1st and 3rd quartiles 61 and 76, respectively), similar for males and females. Our analysis data set consisted of a total of 26 941 relatives of the 9143 leukemia cases and 117 088 relatives of their 36 354 matched controls. Table 1 presents the numbers of relatives of case and control probands and the number of CLL cases identified among these relatives.
We used Cox regression to compare the risk of CLL in first-degree relatives of case probands and first-degree relatives of controls, stratifying by type of kinship and sex. These relative risks are presented as cause-specific hazard ratios (HRs) from Cox models, with relatives as the units of analysis and age as the time scale. Thus, observation time began from the age of 15 years (left truncated in 1958) and subjects did not contribute to the risk set at any time after the date of death, emigration, diagnosis of another malignant cancer (or different leukemia) or end of the observation period (31 December 2007). The outcome of interest was age at diagnosis of CLL in the relative. The overall HR for relatives of CLL cases compared with relatives of controls was adjusted for sex, birth cohort, relationship to the proband and sex of the proband.
CLL exhibited a strong familial aggregation in our population with an overall HR ¼ 7.7 (95% confidence interval (CI): 6.00, 9.87) consistent with those reported by Goldin et al. 2 The relative risks for each type of relative are presented on a pedigree diagram (see Figure 1 ). There was no evidence of any of these relative risks changing over calendar time (data not shown). The highest relative risks were for same-sex siblings of both female probands (HR ¼ 28.52; 95% CI: 3.43, 237.26) and male probands (HR ¼ 14.60; 95% CI: 5.71, 37.30). In additional analyses of siblings, with the age of the proband included in our models, we found no evidence of a correlation between the age at onset of CLL in siblings. To remove the potential genetic confounding due to twins, we excluded 16 sibling pairs born on the same day, but this had little or no effect on the estimates. In addition to the high risks for same-sex siblings, we also observed some other interesting sex differences in our data. Sons had a much higher risk than daughters, especially if the affected parent was the mother (HR ¼ 23.51; 95% CI: 6.92, 79.90), and mothers of affected children had higher risk than fathers (HR ¼ 10.32; 95% CI: 5.55, 19.19). As a supplementary analysis to investigate the potential contribution of shared environmental exposure, we extracted from our data all CLL cases with children, defining the other parent of the child as their spouse (n ¼ 9196). Using the n ¼ 34 493 spouses of the matched controls as the reference group, we found no evidence of an increased risk of CLL in the spouses of cases.
The strengths of our study include the availability of populationbased cancer registration data for an extended calendar period, with high completeness 5 and comparable coding (ICD7) of leukemia used throughout the period in addition to the most current coding system. This is particularly important for a cancer such as leukemia for which classification is difficult and subject to change. 6 However, we lacked information on risk factors (for example, environmental exposures) and on clinical details such as biological markers.
The striking familial aggregation we observed for CLL is consistent with an inherited genetic effect that has been proposed for some time, 2 with evidence accumulated from family studies 7, 8 and linkage studies. 9 Recent association studies have identified common variants associated with susceptibility to CLL, 10-13 but these may only account for a small proportion of the genetic risk. 13, 14 The lack of any increased risk for spouses in our data suggests that shared adult environment is not an important factor for familial CLL, but further work is necessary to assess the possible contribution of childhood environment, which may be reflected by the high risks observed for same-sex siblings. Overall, our work suggests that there is opportunity for improvement in the design, and thus the statistical power, of studies of familial CLL. We propose that in studies of familial CLL, consideration of sex and kinship may be crucial to the genotyping of informative subjects for genetic discovery.
Systemic microRNA-34a delivery induces apoptosis and abrogates growth of diffuse large B-cell lymphoma in vivo Diffuse large B-cell lymphoma (DLBCL) accounts for B30% of all B-cell lymphomas. The standard therapy consists of three chemotherapeutics (cyclophosphamide, doxorubicin and vincristine) combined with the steroid prednisone (CHOP) and/or the CD20-specific antibody rituximab. 1 Two major subtypes of DLBCL are distinguished based on gene expression profiles that resemble those of activated B cells and germinal center B cells (ABC and GC types). 2 We have reported recently that the expression of posttranscriptionally active small regulatory RNAs (microRNAs (miRNAs)) with tumor-suppressive properties [3] [4] [5] is strongly deregulated in both nodal and extranodal DLBCL relative to indolent lymphomas arising at the same sites. 6 All examined DLBCL cases exhibited a consistent signature of downregulated miRNAs independent of their location, which shared the common feature of being repressed by the transcription factor Myc. Myc was indeed found to be overexpressed in most analyzed cases of extranodal DLBCL, but not the corresponding indolent lymphomas. One miRNA in particular, miR-34a, emerged as a potent tumor-suppressor miRNA with the potential to inhibit the proliferation of various DLBCL cell lines. 6 The tumor-suppressive activity of miR-34a could be attributed to the specific knockdown of FoxP1, a transcription factor and known target of miR-34a, 6, 7 whose overexpression is associated with inferior prognosis in DLBCL patients.
